JP3579345B2 - ４−カルボキシアミノ−２−置換−１，２，３，４−テトラヒドロキノリンの製造方法 - Google Patents

４−カルボキシアミノ−２−置換−１，２，３，４−テトラヒドロキノリンの製造方法 Download PDF

Info

Publication number
JP3579345B2
JP3579345B2 JP2000362153A JP2000362153A JP3579345B2 JP 3579345 B2 JP3579345 B2 JP 3579345B2 JP 2000362153 A JP2000362153 A JP 2000362153A JP 2000362153 A JP2000362153 A JP 2000362153A JP 3579345 B2 JP3579345 B2 JP 3579345B2
Authority
JP
Japan
Prior art keywords
trifluoromethyl
quinoline
dihydro
ethyl
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000362153A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001163859A (ja
Inventor
バーンズ デイモン デビッド
ウェイン ダッガー ロバート
Original Assignee
ファイザー・プロダクツ・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・プロダクツ・インク filed Critical ファイザー・プロダクツ・インク
Publication of JP2001163859A publication Critical patent/JP2001163859A/ja
Application granted granted Critical
Publication of JP3579345B2 publication Critical patent/JP3579345B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Quinoline Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2000362153A 1999-11-30 2000-11-29 ４−カルボキシアミノ−２−置換−１，２，３，４−テトラヒドロキノリンの製造方法 Expired - Fee Related JP3579345B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16796799P 1999-11-30 1999-11-30
US60/167967 1999-11-30

Publications (2)

Publication Number Publication Date
JP2001163859A JP2001163859A (ja) 2001-06-19
JP3579345B2 true JP3579345B2 (ja) 2004-10-20

Family

ID=22609556

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000362153A Expired - Fee Related JP3579345B2 (ja) 1999-11-30 2000-11-29 ４−カルボキシアミノ−２−置換−１，２，３，４−テトラヒドロキノリンの製造方法

Country Status (44)

Country Link
US (1) US6313142B1 (enExample)
EP (1) EP1125929B1 (enExample)
JP (1) JP3579345B2 (enExample)
KR (1) KR100408177B1 (enExample)
CN (1) CN1173953C (enExample)
AP (1) AP2000002011A0 (enExample)
AR (1) AR029775A1 (enExample)
AT (1) ATE315028T1 (enExample)
AU (1) AU784694B2 (enExample)
BG (1) BG105009A (enExample)
BR (1) BR0005636A (enExample)
CA (1) CA2327029C (enExample)
CO (1) CO5261552A1 (enExample)
CY (1) CY1104989T1 (enExample)
CZ (1) CZ20004407A3 (enExample)
DE (1) DE60025317T2 (enExample)
DK (1) DK1125929T3 (enExample)
DZ (1) DZ3079A1 (enExample)
EA (1) EA003668B1 (enExample)
EE (1) EE200000659A (enExample)
ES (1) ES2254109T3 (enExample)
GE (1) GEP20022798B (enExample)
GT (1) GT200000190A (enExample)
HN (1) HN2000000203A (enExample)
HR (1) HRP20000804A2 (enExample)
HU (1) HUP0004747A3 (enExample)
ID (1) ID28489A (enExample)
IL (1) IL139849A (enExample)
IS (1) IS5715A (enExample)
MA (1) MA25223A1 (enExample)
NO (1) NO20006039L (enExample)
NZ (1) NZ508509A (enExample)
OA (1) OA11494A (enExample)
PA (1) PA8503801A1 (enExample)
PE (1) PE20010913A1 (enExample)
PL (1) PL344208A1 (enExample)
SG (1) SG102603A1 (enExample)
SK (1) SK17792000A3 (enExample)
TN (1) TNSN00230A1 (enExample)
TW (1) TW591016B (enExample)
UA (1) UA65615C2 (enExample)
UY (1) UY26451A1 (enExample)
YU (1) YU71500A (enExample)
ZA (1) ZA200006947B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
IL162533A0 (en) * 2001-12-19 2005-11-20 Atherogenics Inc Chalcone derivatives and their use to treat diseases
WO2003053359A2 (en) 2001-12-19 2003-07-03 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
ATE410521T1 (de) * 2002-04-11 2008-10-15 Roar Holding Llc Ex-vivo-verfahren zur bestimmung der cetp- aktivität und der wirksamkeit der behandlung von herzerkrankungen
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) * 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
PL376156A1 (en) * 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US7223870B2 (en) 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
WO2004056727A2 (en) * 2002-12-19 2004-07-08 Atherogenics, Inc. Process of making chalcone derivatives
EP1961419B1 (en) 2002-12-20 2010-03-24 Pfizer Products Inc. Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
EP1601655A2 (en) * 2003-03-04 2005-12-07 Takasago International Corporation Method for producing optically active amines
AU2004222436A1 (en) * 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of S-(2-(((1- (2-ethylbutyl) cyclohexyl)carbonyl) amino) phenyl)-2-methylpropanethioate
PT1603553E (pt) * 2003-03-17 2012-02-03 Japan Tobacco Inc Composições farmacêuticas de inibidores de cetp
TWI494102B (zh) * 2003-05-02 2015-08-01 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
PL1670768T3 (pl) * 2003-10-08 2010-01-29 Lilly Co Eli Związki i sposoby leczenia dyslipidemii
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
JP2008504266A (ja) * 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物及び方法
DOP2005000123A (es) * 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
WO2006069162A1 (en) * 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
BRPI0608553A2 (pt) * 2005-02-24 2010-01-12 Millennium Pharm Inc antagonistas de receptor de pgd2 para o tratamento de doenças inflamatórias
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
TW200901959A (en) 2007-03-09 2009-01-16 Indigene Pharmaceuticals Inc Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
CN101429160B (zh) * 2007-11-06 2011-10-19 上海药明康德新药开发有限公司 一种1-r-4-氨基-1,2,3,4-四氢喹啉的合成方法
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
PE20251749A1 (es) 2022-07-05 2025-07-09 Newamsterdam Pharma B V Sales de obicetrapib y procesos para su fabricacion y productos intermedios de estos

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7870M (enExample) * 1968-11-08 1970-04-27
US3971789A (en) 1972-10-21 1976-07-27 John Wyeth & Brother Limited O-(4-Quinolylamino)benzamides
GB8432091D0 (en) 1984-12-19 1985-01-30 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
US4839368A (en) 1986-05-02 1989-06-13 Mochida Pharmaceutical Co., Ltd. 1-acyl-2,3-dihydro-4(1H)-quinolinone-4-oxime derivatives
GB8804444D0 (en) 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
US5231102A (en) 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6140342A (en) 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.

Also Published As

Publication number Publication date
PE20010913A1 (es) 2001-09-10
DZ3079A1 (fr) 2004-10-24
CA2327029A1 (en) 2001-05-30
HUP0004747A2 (hu) 2001-10-28
EA200001129A3 (ru) 2001-10-22
EE200000659A (et) 2001-08-15
IL139849A0 (en) 2002-02-10
YU71500A (sh) 2003-02-28
DE60025317T2 (de) 2006-08-03
PL344208A1 (en) 2001-06-04
MA25223A1 (fr) 2001-07-02
EP1125929B1 (en) 2006-01-04
UA65615C2 (uk) 2004-04-15
NO20006039D0 (no) 2000-11-29
EA003668B1 (ru) 2003-08-28
DK1125929T3 (da) 2006-04-03
HN2000000203A (es) 2001-06-13
JP2001163859A (ja) 2001-06-19
CO5261552A1 (es) 2003-03-31
ES2254109T3 (es) 2006-06-16
CZ20004407A3 (cs) 2002-06-12
US6313142B1 (en) 2001-11-06
ID28489A (id) 2001-05-31
SK17792000A3 (sk) 2002-10-08
AP2000002011A0 (en) 2000-12-31
KR20010052012A (ko) 2001-06-25
OA11494A (en) 2004-05-07
ATE315028T1 (de) 2006-02-15
AR029775A1 (es) 2003-07-16
CA2327029C (en) 2005-08-09
AU784694B2 (en) 2006-06-01
ZA200006947B (en) 2002-05-27
HUP0004747A3 (en) 2002-12-28
SG102603A1 (en) 2004-03-26
HU0004747D0 (enExample) 2001-02-28
NO20006039L (no) 2001-05-31
DE60025317D1 (de) 2006-03-30
BR0005636A (pt) 2001-07-17
EP1125929A1 (en) 2001-08-22
CN1173953C (zh) 2004-11-03
GEP20022798B (en) 2002-09-25
PA8503801A1 (es) 2002-07-30
TNSN00230A1 (fr) 2005-11-10
CY1104989T1 (el) 2010-03-03
HRP20000804A2 (en) 2001-06-30
GT200000190A (es) 2002-04-27
NZ508509A (en) 2001-06-29
KR100408177B1 (ko) 2003-12-01
IL139849A (en) 2006-10-31
TW591016B (en) 2004-06-11
UY26451A1 (es) 2001-06-29
IS5715A (is) 2001-05-31
HK1038007A1 (en) 2002-03-01
BG105009A (en) 2001-11-30
AU7178900A (en) 2001-05-31
CN1302800A (zh) 2001-07-11
EA200001129A2 (ru) 2001-06-25

Similar Documents

Publication Publication Date Title
EP1125929B1 (en) Method for making (-)-(2R,4S)-4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonylamino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester
MXPA02005354A (es) Cristal de 4-carboxamino-1,2,3,4-tetrahidroquinolina 2-sustituida.
JP3076003B2 (ja) 置換された４−（キノリン−２−イル−メトキシ）フエニル酢酸誘導体及びその塩
JP4108129B2 (ja) Ｅａａアンタゴニストとしてのテトラヒドロキノリン誘導体
PL198124B1 (pl) 4-Amino-podstawione-2-podstawione-1,2,3,4-tetrahydrochinoliny,środek farmaceutyczny i zastosowanie 4-amino-podstawionych-2-podstawionych-1,2,3,4-tetrahydrochinolin
JP2002526477A (ja) Ｃｅｔｐ阻害剤としての４−カルボキシアミノ−２−メチル−１，２，３，４−テトラヒドロキノリン類
CZ20032900A3 (cs) Sloučeniny vhodné jako meziprodukty
KR20170102204A (ko) 테트라하이드로퀴놀린 유도체 제조용의 합성 중간체를 제조하기 위한 방법
AU2010294277B2 (en) 5- (3, 4-dichloro-phenyl) -N- (2-hydroxy-cyclohexyl) -6- (2,2, 2-trifluoro-ethoxy) -nico tinamide and salts thereof as HDL cholesterol raising agents
TW200825068A (en) A new method for preparing 4,4'-(1-methyl-1,2-ethandiyl)-BIS-(2,6-piperazinedione)
NZ245327A (en) Quinolylmethoxyphenyl-acetamides, preparation and pharmaceutical compositions thereof
HK1038007B (en) Method for making 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline
MXPA00011855A (en) Method for making (-)-(2r,4s)-4- [(3,5-bis- trifluoromethyl-benzyl)- methoxycarbonylamino]- 2-ethyl-6- trifluoromethyl-3,4-dihydro- 2h-quinoline- 1-carboxylic acid ethyl ester
FR2753968A1 (fr) Nouvelles heteroaryloxyethylamines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
HK1172021B (en) 5-(3,4-dichloro-phenyl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-ethoxy)-nicotinamide and salts thereof as hdl cholesterol raising agents

Legal Events

Date Code Title Description
TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20040616

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20040715

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20070723

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080723

Year of fee payment: 4

LAPS Cancellation because of no payment of annual fees